4 newsletters, ranked by editorial quality and how recently they published. Looking for something more specific? Search instead.
BioCompounding is an investment-research newsletter covering biotech, medtech and pharma companies and sector economics, such as generics versus biosimilars and company deep-dives on earnings and business models. Readers get explanations of industry mechanics and equity analysis of specific firms like Intuitive Surgical and Edwards Lifesciences.
Tracks small and mid-cap biotech companies seen as potential acquisition targets, with M&A and growth scores, catalysts, risks and valuation commentary drawn from conference presentations. Also includes occasional market history posts.
Long-form articles on clinical trial operations, covering patient enrollment, site sustainability and where trial research is heading. Draws on conference observations from SCRS 2026 and trend analysis aimed at sponsors, CROs and research sites.
The Signal is a weekly-style briefing on how AI is moving into healthcare, pharma and enterprise decision-making, with each issue pairing a news item with what it means for pharma, medical affairs and market access teams. Readers get concise context on regulation, clinical trials and governance developments, framed around practical implications.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
